Halozyme治疗主任Matthew L. Posard在8月14日出售了价值570 133 70美元的股票。 Halozyme Therapeutics Director Matthew L. Posard sold $570,133.70 worth of shares on Aug 14.

Halozyme治疗主任Matthew L. Posard在8月14日出售了该公司9 881股股票,价值570 133 70美元,其余股票价值403 M美元。 Halozyme Therapeutics Director Matthew L. Posard sold 9,881 shares of the company's stock for $570,133.70 on Aug 14, with remaining shares valued at $4.03M. 生物制药公司报告,该季度净利润为36.94%、225.71%的ROE和0.91美元的EPS,超过了分析师的估计。 The biopharmaceutical firm reported a 36.94% net margin, 225.71% ROE, and EPS of $0.91 for the quarter, surpassing analyst estimates. 该公司的市场上限为7.56B、P/E 24.65、贝塔1.27。 The company has a market cap of $7.56B, P/E 24.65, beta 1.27.